Ryeqo approved for endometriosis, pending PBS subsidy
ABC News — March 2, 2024, 04:00 AM UTC
Summary: The Therapeutic Goods Administration has approved Ryeqo, the first new treatment for endometriosis in 13 years. The drug, pending PBS subsidy, costs approximately $135 per month. Endometriosis affects one in seven women and causes symptoms like heavy bleeding and severe pain. Ryeqo, a single-pill alternative, is aimed at managing symptomatic endometriosis by suppressing hormone production. However, its high cost may create an economic burden for patients.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.